Dermapharm Holding SE (DMPD.XC)
- Previous Close
38.88 - Open
38.88 - Bid 43.78 x --
- Ask 44.58 x --
- Day's Range
38.88 - 38.88 - 52 Week Range
38.88 - 47.97 - Volume
35 - Avg. Volume
0 - Market Cap (intraday)
2.093B - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
20.25 - EPS (TTM)
1.92 - Earnings Date Aug 26, 2025
- Forward Dividend & Yield 0.90 (2.32%)
- Ex-Dividend Date Jun 27, 2025
- 1y Target Est
--
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, France, Spain, Austria, Switzerland, and internationally. The company operates through three segments: Branded Pharmaceuticals, Other Healthcare Products, and Parallel Import Business. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, and Herpotherm brands. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-AG.
ir.dermapharm.de3,610
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DMPD.XC
View MorePerformance Overview: DMPD.XC
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DMPD.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DMPD.XC
View MoreValuation Measures
Market Cap
1.95B
Enterprise Value
2.81B
Trailing P/E
20.25
Forward P/E
16.21
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.77
Price/Book (mrq)
3.28
Enterprise Value/Revenue
2.32
Enterprise Value/EBITDA
9.03
Financial Highlights
Profitability and Income Statement
Profit Margin
8.64%
Return on Assets (ttm)
6.40%
Return on Equity (ttm)
16.57%
Revenue (ttm)
1.2B
Net Income Avi to Common (ttm)
103.57M
Diluted EPS (ttm)
1.92
Balance Sheet and Cash Flow
Total Cash (mrq)
115.18M
Total Debt/Equity (mrq)
154.98%
Levered Free Cash Flow (ttm)
79.2M